T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$18.7B |
| 2 |
Apple
AAPL
|
+$5.48B |
| 3 |
NVIDIA
NVDA
|
+$5.33B |
| 4 |
Tesla
TSLA
|
+$4.47B |
| 5 |
Microsoft
MSFT
|
+$2.15B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$4.26B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.3B |
| 3 |
Morgan Stanley
MS
|
+$2.82B |
| 4 |
Global Payments
GPN
|
+$2.43B |
| 5 |
PayPal
PYPL
|
+$2B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.36% |
| 2 | Healthcare | 16.09% |
| 3 | Consumer Discretionary | 15.79% |
| 4 | Communication Services | 12.38% |
| 5 | Financials | 10.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TFFP
2751
DELISTED
TFF Pharmaceuticals, Inc. Common Stock
TFFP
| $201K | ﹤0.01% |
908
+248
| +38% | +$48K |
|
|
CSSE
2752
DELISTED
Chicken Soup for the Soul Entertainment, Inc. Class A Common Stock
CSSE
| $200K | ﹤0.01% |
+14,444
| New | +$250K |
|
|
EXPR
2753
DELISTED
Express, Inc.
EXPR
| $199K | ﹤0.01% |
+3,237
| New | +$254K |
|
2754
Globalstar
GSAT
$10.7B
| $197K | ﹤0.01% |
11,324
-22,575
| -67% | -$495K |
|
2755
Tencent Music
TME
$14B
| $197K | ﹤0.01% |
28,800
-2,642,533
| -99% | -$19.5M |
|
2756
PharmaCyte Biotech
PMCB
$6M
| $195K | ﹤0.01% |
78,100
-55,500
| -42% | -$153K |
|
|
KALV
2757
DELISTED
KalVista Pharmaceuticals
KALV
| $194K | ﹤0.01% |
+14,661
| New | +$233K |
|
|
BLUE
2758
DELISTED
bluebird bio
BLUE
| $192K | ﹤0.01% |
959
-1,222
| -56% | -$288K |
|
2759
NN Inc
NNBR
$298M
| $191K | ﹤0.01% |
46,657
-700
| -1% | -$3.43K |
|
2760
PureCycle Technologies
PCT
$1.44B
| $191K | ﹤0.01% |
+19,941
| New | +$240K |
|
2761
Aveanna Healthcare
AVAH
$2.33B
| $190K | ﹤0.01% |
+25,632
| New | +$186K |
|
|
SELF
2762
Global Self Storage
SELF
$59M
| $190K | ﹤0.01% |
33,399
| – | – |
|
|
PRMW
2763
DELISTED
Primo Water Corporation
PRMW
| $189K | ﹤0.01% |
10,712
-2,700
| -20% | -$46.3K |
|
2764
Kopin
KOPN
$892M
| $187K | ﹤0.01% |
45,700
-1,600
| -3% | -$8.13K |
|
2765
Pulse Biosciences
PLSE
$3.19B
| $187K | ﹤0.01% |
12,645
+2,200
| +21% | +$43.8K |
|
|
KYNB
2766
Kyntra Bio
KYNB
$28.7M
| $186K | ﹤0.01% |
529
-736
| -58% | -$229K |
|
2767
Golub Capital BDC
GBDC
$3.47B
| $185K | ﹤0.01% |
12,000
| – | – |
|
2768
iBio
IBIO
$70M
| $185K | ﹤0.01% |
674
+369
| +121% | +$141K |
|
2769
Microvast
MVST
$343M
| $185K | ﹤0.01% |
+32,600
| New | +$257K |
|
2770
Lipocine
LPCN
$17.3M
| $183K | ﹤0.01% |
10,862
+282
| +3% | +$5.24K |
|
2771
Goldgroup Mining Inc.
GORO
$210M
| $180K | ﹤0.01% |
115,660
+26,200
| +29% | +$47.6K |
|
2772
Shattuck Labs
STTK
$749M
| $180K | ﹤0.01% |
+21,116
| New | +$291K |
|
|
HARP
2773
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $179K | ﹤0.01% |
2,373
+890
| +60% | +$60.7K |
|
2774
Delek US
DK
$4.18B
| $177K | ﹤0.01% |
11,821
-1,097
| -8% | -$19.4K |
|
2775
Ocean Power Technologies
OPTT
$54.8M
| $177K | ﹤0.01% |
119,800
+36,200
| +43% | +$70.5K |
|
Similar funds
T. Rowe Price Associates's Q4 2021 Portfolio in Review
As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
- T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
- T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
- T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
- T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
- T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.